Navigation Links
Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Date:5/31/2013

LONDON, May 31, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Bellus Health (TSX: BLU), a Canadian pharmaceutical company developing drugs for amyloid-related diseases.

Edison has recently published a comprehensive report examining the investment merits of Bellus Health, focusing on the company's lead programme, Kiacta, currently in a pivotal Phase III trial for amyloid A (AA) amyloidosis, an orphan drug indication affecting up to 50,000 patients worldwide. In the report, Pivotal play in rare kidney disease, Edison's Canadian-based healthcare analyst, Pooya Hemami , argues that Bellus' investment case is underpinned by Kiacta's 60% probability of success in the pivotal study (based on positive trends in a previous Phase II/III study), the potential for premium pricing and a seven- to-10-year orphan drug market exclusivity period. With the Kiacta trial results not expected until 2017, a long-term view is required, but importantly, Bellus is fully funded until the data read out. Based on a risk-adjusted NPV analysis, Edison values Bellus at C$31m, or C$0.74 per share (fully diluted).

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

For the full report see: http://www.edisoninvestmentresearch.com/research/company/bellus-health

The launch of coverage on Bellus Health is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About Bellus Health

Bellus Health is a Canadian pharmaceutical company developing drugs for amyloid-related diseases. Its lead candidate, Kiacta, is in a pivotal Phase III trial for amyloid A (AA) amyloidosis. BLU8499 is expected to start a Phase IIa study in Alzheimer's disease in 2014. Vivimind, a nutraceutical product for memory support, is marketed through distribution agreements with multiple partners in several countries, including Italy, Canada and Greece. For more information, visit http://www.bellushealth.com.

For more information please contact:
Pooya Hemami , Edison Investment Research, +1-514-475-2384
healthcare@edisongroup.com


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
2. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
3. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
4. Edison Pharmaceuticals Closes $20M Series F Financing
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
7. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
8. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
9. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
10. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
11. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... ... October 11, 2019 , ... On ... national resource — held the grand opening for Long Island’s first-of-a-kind boutique CBD ... a thoughtfully curated lineup of CBD wellness products tailored to health-conscious consumers. , ...
(Date:10/10/2019)... ... October 10, 2019 , ... Hospice ... on Thursday, September 26, at the Westchester Country Club in Rye. The event ... of the organization and its mission. , “In Celebration” featured live entertainment, culinary ...
(Date:10/9/2019)... N.C. (PRWEB) , ... October 09, 2019 , ... Drs. ... relief for snorers diagnosed with obstructive sleep apnea in Davidson, NC. If ... cardiovascular disease. When treated under the care of a skilled dentist, those who suffer ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... October 10, 2019 , ... Caring.com, a leading senior care referral service with ... Places for Seniors to Live. All 50 states and 302 cities in the U.S. ... workforce development. , According to the U.S. Census Bureau , almost 20 ...
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can three former ... aging and wellness in the nation? That question will be answered at ICAA 2019: ... Summit and Expo. The event will take place October 10-12, 2019, at the Gaylord ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon Valley Smile ... experience relief from this common and treatable condition. Dr. HagShenas’ goal is to treat ... living with uncomfortable symptoms, including tender and bleeding gums, and to prevent gum disease ...
(Date:10/8/2019)... Md. (PRWEB) , ... October 08, 2019 , ... ... fungal infection progression in live samples, Meiqing Shi, associate professor with the University ... field. In his latest paper published in Nature Communications, Shi and his lab ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... laboratory managers, administrators and pathologists, 4medica® President Gregg Church will inform ... the first-to-market solution reinventing labs orders management-by starting with the right, clean patient ...
Breaking Medicine News(10 mins):